As of March 23, 2026, Travere Therapeutics's top three insider holders are Eric M Dube (Chief Executive Officer, 432.89K shares), Peter Heerma (Chief Commercial Officer, 131.82K shares), Christopher R. Cline (Chief Financial Officer, 111.23K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Eric M Dube | Chief Executive Officer | 432,886 | 0 | 24 Feb, 2026 |
| Peter Heerma | Chief Commercial Officer | 131,823 | 0 | 03 Feb, 2026 |
| Christopher R. Cline | Chief Financial Officer | 111,226 | 0 | 04 Feb, 2026 |
| William E. Rote | Chief Research Officer | 109,087 | 0 | 03 Feb, 2026 |
| Jula Inrig | Chief Medical Officer | 105,706 | 0 | 04 Feb, 2026 |
| Elizabeth E Reed | Chief Legal Officer And Gc | 105,211 | 0 | 18 Mar, 2026 |
| Elizabeth E Reed | Chief Legal Officer And Gc | 105,211 | 0 | 19 Feb, 2026 |
| Jeffrey A Meckler | 87,500 | 0 | 16 May, 2025 | |
| Timothy Coughlin | 55,500 | 0 | 03 Nov, 2025 | |
| Sandra Calvin | Svp, Chief Accounting Officer | 49,080 | 0 | 03 Feb, 2026 |
| Noah L. Rosenberg | Chief Medical Officer | 47,614 | 0 | 17 Aug, 2021 |
| Roy D. Baynes | 37,500 | 0 | 16 May, 2025 | |
| Laura Clague | Chief Financial Officer | 35,655 | 0 | 12 May, 2022 |
| Ron Squarer | 35,375 | 0 | 16 May, 2025 | |
| John A Orwin | 35,375 | 0 | 16 May, 2025 | |
| Sandra Poole | 30,000 | 0 | 16 May, 2025 | |
| Suzanne Louise Bruhn | 28,750 | 0 | 16 May, 2025 | |
| Brinkley Ruth Williams | 25,750 | 0 | 16 May, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 16 Mar, 2026 | Elizabeth E Reed | Common Stock | A | 10,000 | $19.08 | 115,211 | D | M |
| 16 Mar, 2026 | Elizabeth E Reed | Common Stock | D | 10,000 | $28.09 | 105,211 | D | S |
| 16 Mar, 2026 | Elizabeth E Reed | Employee stock option (right to buy) | D | 10,000 | $0.00 | 10,000 | D | M |
| 20 Feb, 2026 | Eric M Dube | Common Stock | A | 60,000 | $15.46 | 492,886 | D | M |
| 20 Feb, 2026 | Eric M Dube | Common Stock | D | 60,000 | $30.10 | 432,886 | D | S |
| 20 Feb, 2026 | Eric M Dube | Employee stock option (right to buy) | D | 60,000 | $0.00 | 60,000 | D | M |
| 17 Feb, 2026 | Elizabeth E Reed | Common Stock | A | 10,000 | $19.08 | 115,211 | D | M |
| 17 Feb, 2026 | Elizabeth E Reed | Common Stock | A | 10,000 | $19.08 | 115,211 | D | M |
| 17 Feb, 2026 | Elizabeth E Reed | Common Stock | D | 5,679 | $27.50 | 109,532 | D | S |
| 17 Feb, 2026 | Elizabeth E Reed | Common Stock | D | 5,679 | $27.50 | 109,532 | D | S |
| 17 Feb, 2026 | Elizabeth E Reed | Common Stock | D | 4,321 | $28.26 | 105,211 | D | S |
| 17 Feb, 2026 | Elizabeth E Reed | Common Stock | D | 4,321 | $28.26 | 105,211 | D | S |
| 17 Feb, 2026 | Elizabeth E Reed | Employee stock option (right to buy) | D | 10,000 | $0.00 | 20,000 | D | M |
| 17 Feb, 2026 | Elizabeth E Reed | Employee stock option (right to buy) | D | 10,000 | $0.00 | 20,000 | D | M |
| 04 Feb, 2026 | Elizabeth E Reed | Common Stock | D | 2,485 | $32.07 | 105,720 | D | S |
| 04 Feb, 2026 | Elizabeth E Reed | Common Stock | D | 2,485 | $32.07 | 105,720 | D | S |
| 04 Feb, 2026 | Jula Inrig | Common Stock | D | 1,547 | $32.11 | 105,938 | D | S |
| 04 Feb, 2026 | Christopher R. Cline | Common Stock | D | 1,635 | $32.14 | 111,336 | D | S |
| 04 Feb, 2026 | Christopher R. Cline | Common Stock | D | 110 | $32.90 | 111,226 | D | S |
| 04 Feb, 2026 | Jula Inrig | Common Stock | D | 232 | $32.85 | 105,706 | D | S |